BR112019006074A2 - heterodímero, método de produção do heterodímero, métodos de produção de um heterodímero, ácido nucleico, vetor ou sistema de vetores, célula, composição farmacêutica e método de tratamento ou prevenção de uma doença ou distúrbio em um sujeito em necessidade do mesmo - Google Patents
heterodímero, método de produção do heterodímero, métodos de produção de um heterodímero, ácido nucleico, vetor ou sistema de vetores, célula, composição farmacêutica e método de tratamento ou prevenção de uma doença ou distúrbio em um sujeito em necessidade do mesmoInfo
- Publication number
- BR112019006074A2 BR112019006074A2 BR112019006074A BR112019006074A BR112019006074A2 BR 112019006074 A2 BR112019006074 A2 BR 112019006074A2 BR 112019006074 A BR112019006074 A BR 112019006074A BR 112019006074 A BR112019006074 A BR 112019006074A BR 112019006074 A2 BR112019006074 A2 BR 112019006074A2
- Authority
- BR
- Brazil
- Prior art keywords
- heterodimer
- producing
- vector
- treating
- disorder
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 239000000833 heterodimer Substances 0.000 title 3
- 208000035475 disorder Diseases 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
a presente invenção proporciona um método para a produção de construtos de imunoglobulina heterodimérica estável e altamente específica, por exemplo, anticorpos biespecíficos, retendo as propriedades desejáveis da igg nativa e tendo ausente o desemparelhamento de cadeia pesada-leve indesejável, que pode simultaneamente ligar duas moléculas alvo e são mais potentes no tratamento de doenças complexas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610863814 | 2016-09-29 | ||
PCT/CN2017/104044 WO2018059502A1 (en) | 2016-09-29 | 2017-09-28 | Heterodimeric immunoglobulin constructs and preparation methods thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019006074A2 true BR112019006074A2 (pt) | 2019-06-18 |
Family
ID=61762488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019006074A BR112019006074A2 (pt) | 2016-09-29 | 2017-09-28 | heterodímero, método de produção do heterodímero, métodos de produção de um heterodímero, ácido nucleico, vetor ou sistema de vetores, célula, composição farmacêutica e método de tratamento ou prevenção de uma doença ou distúrbio em um sujeito em necessidade do mesmo |
Country Status (23)
Country | Link |
---|---|
US (1) | US11498977B2 (pt) |
EP (1) | EP3504234A4 (pt) |
JP (1) | JP7424727B2 (pt) |
KR (1) | KR102242990B1 (pt) |
CN (1) | CN109790215B (pt) |
AU (1) | AU2017336867B2 (pt) |
BR (1) | BR112019006074A2 (pt) |
CA (1) | CA3035681A1 (pt) |
CL (1) | CL2019000836A1 (pt) |
CO (1) | CO2019003133A2 (pt) |
DO (1) | DOP2019000079A (pt) |
EA (1) | EA201990285A1 (pt) |
EC (1) | ECSP19022190A (pt) |
IL (1) | IL265605B2 (pt) |
MX (1) | MX2019003563A (pt) |
MY (1) | MY194994A (pt) |
PE (1) | PE20190576A1 (pt) |
PH (1) | PH12019500655A1 (pt) |
SA (1) | SA519401441B1 (pt) |
SG (2) | SG10201913263SA (pt) |
TN (1) | TN2019000055A1 (pt) |
WO (1) | WO2018059502A1 (pt) |
ZA (1) | ZA201901708B (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102247704B1 (ko) | 2016-11-18 | 2021-05-03 | 북경한미약품 유한공사 | 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법 |
MX2019011748A (es) * | 2017-04-01 | 2020-01-23 | Beijing hanmi pharm co ltd | Anticuerpo biespecífico heterodimérico tipo estructura de anticuerpo natural anti-pd-l1/anti-pd-1 y preparación del mismo. |
JP7231641B2 (ja) * | 2017-12-04 | 2023-03-01 | 北京韓美薬品有限公司 | 天然抗体様構造を有し、ヘテロ二量体形態の抗pd-l1/抗cd47二重特異性抗体、ならびにその製造方法 |
WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
CN111712522A (zh) | 2018-02-11 | 2020-09-25 | 北京韩美药品有限公司 | 抗pd-1/抗vegf天然抗体结构样异源二聚体形式双特异抗体及其制备 |
US20210139582A1 (en) * | 2018-02-13 | 2021-05-13 | The Brigham And Women's Hospital, Inc. | Therapeutic fcrn-based bispecific monoclonal antibodies |
US20220010006A1 (en) * | 2018-11-05 | 2022-01-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-tnfalpha/anti il - 17a natural antibody structure-like heterodimer form of bispecific antibody and preparation method therefor |
JOP20210298A1 (ar) | 2019-05-14 | 2023-01-30 | Provention Bio Inc | طرق وتركيبات للوقاية من مرض السكري من النوع الأول |
CN113121697B (zh) * | 2019-12-31 | 2023-06-09 | 周易 | Ch3结构域改造诱导形成的异源二聚体及其制备方法和应用 |
IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
WO2022046658A1 (en) * | 2020-08-24 | 2022-03-03 | Janux Therapeutics, Inc. | Antibodies targeting trop2 and cd3 and uses thereof |
WO2022148410A1 (zh) * | 2021-01-08 | 2022-07-14 | 北京韩美药品有限公司 | 抗pd-l1/抗4-1bb天然抗体结构样异源二聚体形式双特异抗体及其制备 |
WO2022159984A1 (en) * | 2021-01-22 | 2022-07-28 | Bionecure Therapeutics, Inc. | Anti-her-2/trop-2 constructs and uses thereof |
KR20230060546A (ko) | 2021-10-22 | 2023-05-04 | 상트네어바이오사이언스 주식회사 | 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
CN114539420B (zh) * | 2022-01-20 | 2024-05-17 | 荣昌生物制药(烟台)股份有限公司 | 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用 |
KR20240135654A (ko) * | 2022-01-26 | 2024-09-11 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 항-her2/trop2 항체 및 이의 용도 |
WO2023164640A1 (en) * | 2022-02-24 | 2023-08-31 | Xencor, Inc. | Anti-cd28 x anti-trop2 antibodies |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL9100352A (nl) | 1991-02-27 | 1992-09-16 | Hoogovens Groep Bv | Werkwijze voor het vervaardigen van ijzerfolie door elektrodepositie. |
DE4429450A1 (de) * | 1993-08-25 | 1995-03-02 | Osberger Helmut Jun | Hefe-Frischzellen-Enzym-Getränk |
US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
CN1260249C (zh) | 1998-05-06 | 2006-06-21 | 基因技术股份有限公司 | 用离子交换层析纯化蛋白质 |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
US20060074225A1 (en) | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
BRPI0812913B8 (pt) | 2007-06-18 | 2021-05-25 | Merck Sharp & Dohme | anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos |
WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
EA201171259A1 (ru) | 2009-04-22 | 2012-05-30 | Мерк Патент Гмбх | Антительные гибридные белки с модифицированными сайтами связывания fcrn |
JP2013511281A (ja) * | 2009-11-23 | 2013-04-04 | アムジェン インコーポレイテッド | 単量体抗体Fc |
PT2635607T (pt) | 2010-11-05 | 2019-12-11 | Zymeworks Inc | Design de anticorpo heterodimérico estável com mutações no domínio do fc |
CN103608357B (zh) | 2011-03-25 | 2018-03-16 | 格兰马克药品股份有限公司 | 异二聚体免疫球蛋白 |
RU2625034C2 (ru) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
RS59166B1 (sr) | 2011-10-27 | 2019-10-31 | Genmab As | Proizvodnja heterodimernih proteina |
PT2773671T (pt) | 2011-11-04 | 2021-12-14 | Zymeworks Inc | Geração de anticorpo heterodimérico estável com mutações no domínio fc |
KR20200126007A (ko) | 2012-04-20 | 2020-11-05 | 메뤼스 엔.페. | Ig-유사 분자의 제조방법 및 제조수단 |
CN104968685A (zh) | 2012-09-25 | 2015-10-07 | 格兰马克药品股份有限公司 | 异源二聚免疫球蛋白的纯化 |
CA2889951C (en) | 2012-11-02 | 2023-04-18 | Zymeworks Inc. | Crystal structures of heterodimeric fc domains |
US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
KR102411491B1 (ko) * | 2012-11-28 | 2022-06-22 | 자임워크스 인코포레이티드 | 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도 |
CN110183534A (zh) | 2012-12-03 | 2019-08-30 | 诺夫免疫股份有限公司 | 抗cd47抗体及其使用方法 |
KR102232153B1 (ko) | 2013-08-20 | 2021-03-24 | 머크 샤프 앤드 돔 코포레이션 | Pd-1 길항제와 디나시클립의 조합을 사용한 암의 치료 |
LT3083686T (lt) | 2013-12-17 | 2020-01-10 | F. Hoffmann-La Roche Ag | Vėžinių ligų gydymo būdai naudojant pd-1 ašies rišimosi antagonistus ir taksanus |
WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
PT3180363T (pt) | 2014-08-15 | 2019-11-05 | Merck Patent Gmbh | Proteínas de fusão de sirp-alfa e imunoglobulina |
WO2016057933A1 (en) | 2014-10-10 | 2016-04-14 | Global Biopharma, Inc. | Methods for treating and/or preventing a tumor growth, invasion and/or metastasis |
KR102489471B1 (ko) | 2014-12-30 | 2023-01-18 | 셀진 코포레이션 | 항-cd47 항체 및 그 용도 |
US20180318417A1 (en) | 2015-01-14 | 2018-11-08 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
WO2016170039A1 (en) | 2015-04-23 | 2016-10-27 | F. Hoffmann-La Roche Ag | Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death 1 polypeptide |
TW201709929A (zh) | 2015-06-12 | 2017-03-16 | 宏觀基因股份有限公司 | 治療癌症的聯合療法 |
CN105111314B (zh) | 2015-08-13 | 2019-01-08 | 成都百世博生物技术有限公司 | 一种新型融合蛋白、药物组合物及其制备方法和用途 |
CN105175545B (zh) | 2015-10-20 | 2019-01-25 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd-1双功能抗体及其应用 |
CN106883297B (zh) | 2015-12-16 | 2019-12-13 | 苏州康宁杰瑞生物科技有限公司 | 基于ch3结构域的异二聚体分子、其制备方法及用途 |
CN108779182A (zh) | 2015-12-28 | 2018-11-09 | 麻省理工学院 | 具有恒定区突变的双特异性抗体及其用途 |
WO2017167350A1 (en) | 2016-03-30 | 2017-10-05 | Horst Lindhofer | Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract |
GB201611530D0 (en) | 2016-07-01 | 2016-08-17 | Alligator Bioscience Ab | Novel polypeptides |
CA3008775A1 (en) | 2016-10-15 | 2018-04-19 | Innovent Biologics (Suzhou) Co., Ltd | Pd-1 antibodies |
KR102247704B1 (ko) * | 2016-11-18 | 2021-05-03 | 북경한미약품 유한공사 | 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법 |
MX2019011748A (es) * | 2017-04-01 | 2020-01-23 | Beijing hanmi pharm co ltd | Anticuerpo biespecífico heterodimérico tipo estructura de anticuerpo natural anti-pd-l1/anti-pd-1 y preparación del mismo. |
AR112603A1 (es) | 2017-07-10 | 2019-11-20 | Lilly Co Eli | Anticuerpos biespecíficos inhibidores de punto de control |
CN107325184A (zh) | 2017-08-08 | 2017-11-07 | 安徽大学 | 一种靶向egfr和her2的双特异性抗体及其应用 |
EA039662B1 (ru) | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Антитела, специфичные к cd47 и pd-l1 |
JP7231641B2 (ja) * | 2017-12-04 | 2023-03-01 | 北京韓美薬品有限公司 | 天然抗体様構造を有し、ヘテロ二量体形態の抗pd-l1/抗cd47二重特異性抗体、ならびにその製造方法 |
WO2019153200A1 (zh) * | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
CN111712522A (zh) * | 2018-02-11 | 2020-09-25 | 北京韩美药品有限公司 | 抗pd-1/抗vegf天然抗体结构样异源二聚体形式双特异抗体及其制备 |
US20220010006A1 (en) * | 2018-11-05 | 2022-01-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-tnfalpha/anti il - 17a natural antibody structure-like heterodimer form of bispecific antibody and preparation method therefor |
-
2017
- 2017-09-28 TN TNP/2019/000055A patent/TN2019000055A1/en unknown
- 2017-09-28 EA EA201990285A patent/EA201990285A1/ru unknown
- 2017-09-28 EP EP17854952.3A patent/EP3504234A4/en active Pending
- 2017-09-28 SG SG10201913263SA patent/SG10201913263SA/en unknown
- 2017-09-28 JP JP2019516702A patent/JP7424727B2/ja active Active
- 2017-09-28 CN CN201780060756.7A patent/CN109790215B/zh active Active
- 2017-09-28 PE PE2019000733A patent/PE20190576A1/es unknown
- 2017-09-28 SG SG11201901307VA patent/SG11201901307VA/en unknown
- 2017-09-28 US US16/337,854 patent/US11498977B2/en active Active
- 2017-09-28 KR KR1020197009091A patent/KR102242990B1/ko active IP Right Grant
- 2017-09-28 IL IL265605A patent/IL265605B2/en unknown
- 2017-09-28 MX MX2019003563A patent/MX2019003563A/es unknown
- 2017-09-28 BR BR112019006074A patent/BR112019006074A2/pt unknown
- 2017-09-28 AU AU2017336867A patent/AU2017336867B2/en active Active
- 2017-09-28 MY MYPI2019001672A patent/MY194994A/en unknown
- 2017-09-28 CA CA3035681A patent/CA3035681A1/en active Pending
- 2017-09-28 WO PCT/CN2017/104044 patent/WO2018059502A1/en unknown
-
2019
- 2019-03-19 ZA ZA2019/01708A patent/ZA201901708B/en unknown
- 2019-03-26 PH PH12019500655A patent/PH12019500655A1/en unknown
- 2019-03-28 DO DO2019000079A patent/DOP2019000079A/es unknown
- 2019-03-28 CL CL2019000836A patent/CL2019000836A1/es unknown
- 2019-03-28 SA SA519401441A patent/SA519401441B1/ar unknown
- 2019-03-29 EC ECSENADI201922190A patent/ECSP19022190A/es unknown
- 2019-03-29 CO CONC2019/0003133A patent/CO2019003133A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3504234A1 (en) | 2019-07-03 |
DOP2019000079A (es) | 2019-11-15 |
PE20190576A1 (es) | 2019-04-22 |
TN2019000055A1 (en) | 2020-07-15 |
PH12019500655A1 (en) | 2019-08-05 |
AU2017336867A1 (en) | 2019-02-28 |
IL265605A (en) | 2019-05-30 |
US20190284299A1 (en) | 2019-09-19 |
EA201990285A1 (ru) | 2019-12-30 |
KR20190055813A (ko) | 2019-05-23 |
SA519401441B1 (ar) | 2022-12-27 |
IL265605B1 (en) | 2024-02-01 |
WO2018059502A1 (en) | 2018-04-05 |
KR102242990B1 (ko) | 2021-04-22 |
SG10201913263SA (en) | 2020-03-30 |
CL2019000836A1 (es) | 2019-08-02 |
US11498977B2 (en) | 2022-11-15 |
JP7424727B2 (ja) | 2024-01-30 |
CA3035681A1 (en) | 2018-04-05 |
NZ750566A (en) | 2024-04-26 |
IL265605B2 (en) | 2024-06-01 |
ZA201901708B (en) | 2022-11-30 |
CN109790215A (zh) | 2019-05-21 |
AU2017336867B2 (en) | 2024-03-14 |
EP3504234A4 (en) | 2020-12-02 |
ECSP19022190A (es) | 2019-05-31 |
JP2019535650A (ja) | 2019-12-12 |
CO2019003133A2 (es) | 2019-04-12 |
SG11201901307VA (en) | 2019-03-28 |
MX2019003563A (es) | 2019-08-12 |
CN109790215B (zh) | 2023-06-30 |
MY194994A (en) | 2022-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019006074A2 (pt) | heterodímero, método de produção do heterodímero, métodos de produção de um heterodímero, ácido nucleico, vetor ou sistema de vetores, célula, composição farmacêutica e método de tratamento ou prevenção de uma doença ou distúrbio em um sujeito em necessidade do mesmo | |
BR112019009316A2 (pt) | anticorpo antirreceptor de transferrina humana, proteína de fusão, fragmento de dna, vetor de expressão, célula de mamífero, complexo de composto farmacologicamente ativo e de anticorpo antirreceptor de transferrina humana, usos do anticorpo antirreceptor de transferrina humana e da proteína de fusão, e, métodos para tratamento de um distúrbio do sistema nervoso central e de uma doença do sistema nervoso central que acompanha a doença de pompe, a síndrome de hurler ou a síndrome de hurler-scheie. | |
BR112017019978A2 (pt) | anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo | |
BR102018008260A2 (pt) | domínios de ligação ao antígeno humanizado e métodos de uso | |
BR112018001161A2 (pt) | proteínas de fusão de ligação a gitr multiespecíficas e multivalentes | |
BR112018007152A2 (pt) | construtos de polipeptídeo de ligação a antígeno compreendendo cadeias leves kappa e lambda e usos dos mesmos | |
CO2018003863A2 (es) | Anticuerpos anti-vegf | |
BR112018076281A2 (pt) | imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo | |
BR112012017124C1 (pt) | Método para produzir e para purificar um multímero polipeptídico | |
EP4374922A3 (en) | Anti-c5 antibodies and uses thereof | |
PE20181044A1 (es) | Anticuerpos anti-pd-1 y composiciones | |
BR112018010385A2 (pt) | anticorpo, receptor de antígeno quimérico, ácido nucleico, célula recombinante, processo para produção de um anticorpo ou um receptor de antígeno quimérico, composição, e, método para detecção de uma célula que expressa cll-1, para diagnóstico de uma doença, para inibição de divisão da célula e para tratamento de um câncer. | |
EA201890302A1 (ru) | Химерные рецепторы антигенов на основе однодоменных антител и способы их применения | |
BR112018015485A2 (pt) | imunoglobulina fabs-in-tandem e usos da mesma | |
BR112018011100A2 (pt) | anticorpo, composição, construto de ácido nucleico, vetor de expressão, célula hospedeira, método para tratamento de um indivíduo que tem um câncer, kit de partes, e, uso de um anticorpo ou de uma composição. | |
BR112016027912A2 (pt) | molécula de ligação triespecífica capaz de se ligar de maneira imunoespecífica a três epítopos diferentes, composição farmacêutica, método de tratamento de câncer, método de tratamento de uma doença associada à presença de um patógeno, anticorpo anti-ror1, ou fragmento de ligação a ror1, fragmento de anticorpo biespecífico, bite ou anticorpo de cadeia simples, e método de tratamento de câncer | |
BR112016030686A2 (pt) | anticorpos anti tau humanizados | |
BR112016013347A2 (pt) | anticorpo monoclonal humano neutralizante anti-il-33 | |
BR112019005316A2 (pt) | anticorpos monoclonais para morte programada 1 (pd-1) | |
BR112016025352A2 (pt) | métodos de produção de uma biblioteca de clones de células eucarióticas, método de produção de um repertório diverso de ligantes, método de triagem para uma célula de um fenótipo desejado, método de triagem para um ligante que reconhece um alvo, biblioteca, biblioteca in vitro de clones de células eucarióticas, recipiente contendo células eucarióticas, uso de uma nuclease específica de sítio, usos da biblioteca, método para converter as populações de anticorpo de cadeia simples (scfv) em imunoglobulina (ig) ou fragmento, e método que permite a reformatação de quaisquer dois elementos de dna unidos a um vetor | |
BR112019002282A2 (pt) | anticorpo que se liga a pd-l1 ou um fragmento de ligação ao antígeno do anticorpo, método para produzir o mesmo e composição para prevenção ou tratamento de câncer ou doenças infecciosas | |
BR112017022255A2 (pt) | anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica | |
EA201491571A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
BR112015021979A2 (pt) | Anticorpos humanos para grem1 | |
BR112017020413A2 (pt) | ?anticorpo anti-notch4 humano? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |